At a glance
- Originator Eli Lilly
- Class Anti-ischaemics; Neuroprotectants; Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cerebral ischaemia
Most Recent Events
- 25 Jun 2001 No-Development-Reported for Cerebral ischaemia in USA (Unknown route)
- 30 Sep 1998 New profile
- 30 Sep 1998 Preclinical development for Cerebral ischaemia in USA (Unknown route)